[Grepafloxacin (Raxar)].
Friis
H M
HM
Klinisk mikrobiologisk afdeling, Centralsygehuset i Slagelse.
D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy / Q000382:microbiology; D000075202:Contraindications; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy / Q000382:microbiology; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014526:Urethritis / Q000188:drug therapy / Q000382:microbiology; D002575:Uterine Cervicitis / Q000188:drug therapy / Q000382:microbiology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; C075375:grepafloxacin